blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3538158

EP3538158 - TREATMENT FOR FIBROSIS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  06.09.2024
Database last updated on 08.04.2026
FormerThe patent has been granted
Status updated on  29.09.2023
FormerGrant of patent is intended
Status updated on  25.06.2023
FormerExamination is in progress
Status updated on  08.07.2020
FormerRequest for examination was made
Status updated on  16.08.2019
FormerThe international publication has been made
Status updated on  18.05.2018
Formerunknown
Status updated on  26.01.2018
Most recent event   Tooltip19.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 21.01.2026  [2026/04]
Applicant(s)For all designated states
Galmed Research and Development Ltd.
16 Zeev Tiomkin Street
6578317 Tel Aviv / IL
[2019/38]
Inventor(s)01 / HAYARDENY-NISSIMOIV, Liat
37 Yehuda Hanasie Street
69391 Tel Aviv / IL
02 / GORFINE, Tali
10 Shtrok Street
6494210 Tel Aviv / IL
03 / BAHARAFF, Allen
7 Hayutman Street
66215441 Tel Aviv / IL
04 / MATO DE LA PAZ, José, M.
9 Asua Avenue
48992 Getxo / ES
 [2019/38]
Representative(s)Pearl Cohen UK
The Gridiron Building
One Pancras Square
London N1C 4AG / GB
[N/P]
Former [2023/44]Pearl Cohen Zedek Latzer Baratz UK LLP
The Gridiron Building
One Pancras Square
London N1C 4AG / GB
Former [2019/38]Pearl Cohen Zedek Latzer Baratz UK LLP
The Gridiron Building
One Pancras Square
London N1C 4AG / GB
Application number, filing date17830003.410.11.2017
[2019/38]
WO2017IB01521
Priority number, dateUS201662420009P10.11.2016         Original published format: US 201662420009 P
US201662420017P10.11.2016         Original published format: US 201662420017 P
US201662420012P10.11.2016         Original published format: US 201662420012 P
US201762475129P22.03.2017         Original published format: US 201762475129 P
[2019/38]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018087599
Date:17.05.2018
Language:EN
[2018/20]
Type: A1 Application with search report 
No.:EP3538158
Date:18.09.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 17.05.2018 takes the place of the publication of the European patent application.
[2019/38]
Type: B1 Patent specification 
No.:EP3538158
Date:01.11.2023
Language:EN
[2023/44]
Search report(s)International search report - published on:EP17.05.2018
ClassificationIPC:A61K47/54, A61K45/06, A61P1/16
[2023/26]
CPC:
A61K31/575 (EP,IL,KR); A61K31/202 (EP,IL,KR); A61K31/4439 (EP,IL,KR);
A61K45/06 (EP,IL,KR); A61K47/54 (IL); A61K47/542 (EP);
A61K47/554 (EP); A61P1/16 (EP,IL,KR); A61P29/00 (EP,IL);
A61P3/06 (EP,IL); A61P3/10 (EP,IL); A61P43/00 (EP,IL);
A61K2300/00 (KR); Y02A50/30 (EP) (-)
C-Set:
A61K31/202, A61K2300/00 (EP);
A61K31/4439, A61K2300/00 (EP)
Former IPC [2019/38]A61K47/54, A61P1/16
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/38]
Extension statesBA06.06.2019
ME06.06.2019
Validation statesMA06.06.2019
MD06.06.2019
TitleGerman:BEHANDLUNG VON FIBROSE[2019/38]
English:TREATMENT FOR FIBROSIS[2019/38]
French:TRAITEMENT DE LA FIBROSE[2019/38]
Entry into regional phase06.06.2019National basic fee paid 
06.06.2019Designation fee(s) paid 
06.06.2019Examination fee paid 
Examination procedure06.06.2019Amendment by applicant (claims and/or description)
06.06.2019Examination requested  [2019/38]
06.06.2019Date on which the examining division has become responsible
13.07.2020Despatch of a communication from the examining division (Time limit: M04)
23.11.2020Reply to a communication from the examining division
11.08.2022Despatch of a communication from the examining division (Time limit: M06)
07.02.2023Reply to a communication from the examining division
26.06.2023Communication of intention to grant the patent
26.09.2023Fee for grant paid
26.09.2023Fee for publishing/printing paid
26.09.2023Receipt of the translation of the claim(s)
Opposition(s)02.08.2024No opposition filed within time limit [2024/41]
Fees paidRenewal fee
06.06.2019Renewal fee patent year 03
13.11.2020Renewal fee patent year 04
19.10.2021Renewal fee patent year 05
15.09.2022Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY10.11.2017
HU10.11.2017
AT01.11.2023
CZ01.11.2023
DK01.11.2023
EE01.11.2023
ES01.11.2023
FI01.11.2023
HR01.11.2023
LT01.11.2023
LV01.11.2023
MC01.11.2023
PL01.11.2023
RO01.11.2023
RS01.11.2023
SE01.11.2023
SI01.11.2023
SK01.11.2023
SM01.11.2023
TR01.11.2023
IE10.11.2023
LU10.11.2023
BE30.11.2023
CH30.11.2023
BG01.02.2024
NO01.02.2024
GR02.02.2024
IS01.03.2024
PT01.03.2024
[2026/04]
Former [2025/39]CY10.11.2017
HU10.11.2017
AT01.11.2023
CZ01.11.2023
DK01.11.2023
EE01.11.2023
ES01.11.2023
FI01.11.2023
HR01.11.2023
LT01.11.2023
LV01.11.2023
MC01.11.2023
PL01.11.2023
RO01.11.2023
RS01.11.2023
SE01.11.2023
SI01.11.2023
SK01.11.2023
SM01.11.2023
IE10.11.2023
LU10.11.2023
BE30.11.2023
CH30.11.2023
BG01.02.2024
NO01.02.2024
GR02.02.2024
IS01.03.2024
PT01.03.2024
Former [2025/36]CY10.11.2017
AT01.11.2023
CZ01.11.2023
DK01.11.2023
EE01.11.2023
ES01.11.2023
FI01.11.2023
HR01.11.2023
LT01.11.2023
LV01.11.2023
MC01.11.2023
PL01.11.2023
RO01.11.2023
RS01.11.2023
SE01.11.2023
SI01.11.2023
SK01.11.2023
SM01.11.2023
IE10.11.2023
LU10.11.2023
BE30.11.2023
CH30.11.2023
BG01.02.2024
NO01.02.2024
GR02.02.2024
IS01.03.2024
PT01.03.2024
Former [2025/33]AT01.11.2023
CZ01.11.2023
DK01.11.2023
EE01.11.2023
ES01.11.2023
FI01.11.2023
HR01.11.2023
LT01.11.2023
LV01.11.2023
MC01.11.2023
PL01.11.2023
RO01.11.2023
RS01.11.2023
SE01.11.2023
SI01.11.2023
SK01.11.2023
SM01.11.2023
IE10.11.2023
LU10.11.2023
BE30.11.2023
CH30.11.2023
BG01.02.2024
NO01.02.2024
GR02.02.2024
IS01.03.2024
PT01.03.2024
Former [2024/49]AT01.11.2023
CZ01.11.2023
DK01.11.2023
EE01.11.2023
ES01.11.2023
HR01.11.2023
LT01.11.2023
LV01.11.2023
MC01.11.2023
PL01.11.2023
RO01.11.2023
RS01.11.2023
SE01.11.2023
SI01.11.2023
SK01.11.2023
SM01.11.2023
IE10.11.2023
LU10.11.2023
BE30.11.2023
CH30.11.2023
BG01.02.2024
NO01.02.2024
GR02.02.2024
IS01.03.2024
PT01.03.2024
Former [2024/47]AT01.11.2023
CZ01.11.2023
DK01.11.2023
EE01.11.2023
ES01.11.2023
HR01.11.2023
LT01.11.2023
LV01.11.2023
MC01.11.2023
PL01.11.2023
RO01.11.2023
RS01.11.2023
SE01.11.2023
SK01.11.2023
SM01.11.2023
IE10.11.2023
LU10.11.2023
BE30.11.2023
CH30.11.2023
BG01.02.2024
NO01.02.2024
GR02.02.2024
IS01.03.2024
PT01.03.2024
Former [2024/46]AT01.11.2023
CZ01.11.2023
DK01.11.2023
EE01.11.2023
ES01.11.2023
HR01.11.2023
LT01.11.2023
LV01.11.2023
MC01.11.2023
PL01.11.2023
RO01.11.2023
RS01.11.2023
SE01.11.2023
SK01.11.2023
SM01.11.2023
IE10.11.2023
LU10.11.2023
CH30.11.2023
BG01.02.2024
NO01.02.2024
GR02.02.2024
IS01.03.2024
PT01.03.2024
Former [2024/40]AT01.11.2023
CZ01.11.2023
DK01.11.2023
EE01.11.2023
ES01.11.2023
HR01.11.2023
LT01.11.2023
LV01.11.2023
MC01.11.2023
PL01.11.2023
RO01.11.2023
RS01.11.2023
SE01.11.2023
SK01.11.2023
SM01.11.2023
LU10.11.2023
CH30.11.2023
BG01.02.2024
NO01.02.2024
GR02.02.2024
IS01.03.2024
PT01.03.2024
Former [2024/36]AT01.11.2023
CZ01.11.2023
DK01.11.2023
EE01.11.2023
ES01.11.2023
HR01.11.2023
LT01.11.2023
LV01.11.2023
PL01.11.2023
RO01.11.2023
RS01.11.2023
SE01.11.2023
SK01.11.2023
SM01.11.2023
LU10.11.2023
CH30.11.2023
BG01.02.2024
NO01.02.2024
GR02.02.2024
IS01.03.2024
PT01.03.2024
Former [2024/35]AT01.11.2023
CZ01.11.2023
DK01.11.2023
EE01.11.2023
ES01.11.2023
HR01.11.2023
LT01.11.2023
LV01.11.2023
PL01.11.2023
RO01.11.2023
RS01.11.2023
SE01.11.2023
SM01.11.2023
LU10.11.2023
CH30.11.2023
BG01.02.2024
NO01.02.2024
GR02.02.2024
IS01.03.2024
PT01.03.2024
Former [2024/34]AT01.11.2023
DK01.11.2023
EE01.11.2023
ES01.11.2023
HR01.11.2023
LT01.11.2023
LV01.11.2023
PL01.11.2023
RS01.11.2023
SE01.11.2023
SM01.11.2023
LU10.11.2023
CH30.11.2023
BG01.02.2024
NO01.02.2024
GR02.02.2024
IS01.03.2024
PT01.03.2024
Former [2024/33]AT01.11.2023
DK01.11.2023
ES01.11.2023
HR01.11.2023
LT01.11.2023
LV01.11.2023
PL01.11.2023
RS01.11.2023
SE01.11.2023
SM01.11.2023
BG01.02.2024
NO01.02.2024
GR02.02.2024
IS01.03.2024
PT01.03.2024
Former [2024/26]AT01.11.2023
ES01.11.2023
HR01.11.2023
LT01.11.2023
LV01.11.2023
PL01.11.2023
RS01.11.2023
SE01.11.2023
BG01.02.2024
NO01.02.2024
GR02.02.2024
IS01.03.2024
PT01.03.2024
Former [2024/25]AT01.11.2023
ES01.11.2023
HR01.11.2023
LT01.11.2023
PL01.11.2023
RS01.11.2023
SE01.11.2023
BG01.02.2024
NO01.02.2024
GR02.02.2024
IS01.03.2024
PT01.03.2024
Former [2024/24]AT01.11.2023
ES01.11.2023
HR01.11.2023
LT01.11.2023
RS01.11.2023
SE01.11.2023
BG01.02.2024
NO01.02.2024
GR02.02.2024
IS01.03.2024
PT01.03.2024
Former [2024/23]AT01.11.2023
ES01.11.2023
LT01.11.2023
BG01.02.2024
GR02.02.2024
IS01.03.2024
PT01.03.2024
Former [2024/21]LT01.11.2023
BG01.02.2024
GR02.02.2024
IS01.03.2024
Former [2024/20]GR02.02.2024
IS01.03.2024
Cited inInternational search[XYI] WO2016112305  (NIMBUS APOLLO INC et al.) [X] 38-40 * claims 1, 4 * * page 3, paragraph 12 *[Y] 1-8,11-35 [I] 1,3,8
 [A] US2011014126  (EVANS RONALD M et al.) [A] 1-40 * page 1, column 1, paragraphs 3-6 *
 [XP] WO2017017677  (GALMED RES AND DEV LTD et al.) [XP] 1-5,7-12,16,17,19,31 * claims 16, 22, 31, 32 * * page 19, lines 11-28 *
 [E] WO2017210526  (CHEMOCENTRYX INC et al.) [E] 1,38-40 * claims 1, 11, 14 *
 [Y]   RIFAAT SAFADI ET AL: "The Fatty Acid-Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease", CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol. 12, no. 12, 9 May 2014 (2014-05-09), US, pages 2085 - 2091.e1, XP055350035, ISSN: 1542-3565, DOI: 10.1016/j.cgh.2014.04.038 [Y] 1-8,11-35 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.cgh.2014.04.038
 [IP]   M. IRUARRIZAGA-LEJARRETA ET AL: "Role of Aramchol in Steatohepatitis and Fibrosis in Mice", HEPATOLOGY COMMUNICATIONS, vol. 1, no. 9, 3 November 2017 (2017-11-03), pages 911 - 927, XP002778683 [IP] 1-40 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.